Glass House Brands (GLAS) Receivables (2020 - 2026)
Glass House Brands (GLAS) posted quarterly Receivables of $6.4 million for Q1 2026, down 4.04% year-over-year from $6.7 million in Q1 2025, and up 45.82% quarter-over-quarter from $4.4 million in Q4 2025.
Glass House Brands (GLAS) Receivables (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has reported Receivables for 7 consecutive years, with $6.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables fell 4.04% year-over-year to $6.4 million; the TTM figure through Mar 2026 stood at $6.4 million (down 4.04% YoY), while the FY2025 annual figure was $4.8 million, down 7.47% from the prior year.
- Receivables advanced to $6.4 million in Q1 2026 per GLAS's latest filing, from $4.4 million in the prior quarter.
- Across five years, Receivables topped out at $9.8 million in Q2 2025 and bottomed at $2.5 million in Q1 2022.
- Historically, Receivables has averaged $5.4 million across 5 years, with a median of $5.2 million in 2024.
- Annual changes were most pronounced in 2022 — Receivables jumped 154.39% — and 2023, when it tumbled 38.13%.
- Glass House Brands' Receivables stood at $5.2 million in 2022, then decreased by 10.38% to $4.7 million in 2023, then advanced by 11.18% to $5.2 million in 2024, then dropped by 15.4% to $4.4 million in 2025, then soared by 45.82% to $6.4 million in 2026.
- Business Quant data shows GLAS's Receivables at $6.4 million in Q1 2026, $4.4 million in Q4 2025, and $6.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 3.07 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 3.49 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 1.57 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 5.84 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 310.30 Mn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 3.67 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 887.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 1.15 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 1.08 Bn |
| 10 | Glass House Brands | 830.21 Mn | 811.66 Mn | 15.77 Mn | 10.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.44 Mn |
| Dec 31, 2025 | 4.42 Mn |
| Sep 30, 2025 | 6.14 Mn |
| Jun 30, 2025 | 9.84 Mn |
| Mar 31, 2025 | 6.71 Mn |
| Dec 31, 2024 | 5.22 Mn |
| Sep 30, 2024 | 7.89 Mn |
| Jun 30, 2024 | 7.72 Mn |
| Mar 31, 2024 | 3.01 Mn |
| Dec 31, 2023 | 4.70 Mn |
| Sep 30, 2023 | 4.20 Mn |
| Jun 30, 2023 | 3.59 Mn |
| Mar 31, 2023 | 3.68 Mn |
| Dec 31, 2022 | 5.24 Mn |
| Sep 30, 2022 | 6.79 Mn |
| Jun 30, 2022 | 3.65 Mn |
| Mar 31, 2022 | 2.52 Mn |
| Dec 31, 2021 | 2.40 Mn |
| Sep 30, 2021 | 2.67 Mn |
| Jun 30, 2021 | 2.52 Mn |